132 related articles for article (PubMed ID: 36005792)
1. Drug Receives New Indication for Juvenile Myelomonocytic Leukemia.
Aschenbrenner DS
Am J Nurs; 2022 Sep; 122(9):25. PubMed ID: 36005792
[TBL] [Abstract][Full Text] [Related]
2. Bridging to transplant with azacitidine in juvenile myelomonocytic leukemia: a retrospective analysis of the EWOG-MDS study group.
Cseh A; Niemeyer CM; Yoshimi A; Dworzak M; Hasle H; van den Heuvel-Eibrink MM; Locatelli F; Masetti R; Schmugge M; Groß-Wieltsch U; Candás A; Kulozik AE; Olcay L; Suttorp M; Furlan I; Strahm B; Flotho C
Blood; 2015 Apr; 125(14):2311-3. PubMed ID: 25838281
[No Abstract] [Full Text] [Related]
3. Azacitidine as a bridge to transplantation in juvenile myelomonocytic leukemia.
Takebayashi A; Yamamoto M; Igarashi K; Muramatsu H; Kawasaki Y
Pediatr Int; 2022 Jan; 64(1):e14929. PubMed ID: 35119175
[No Abstract] [Full Text] [Related]
4. A retrospective analysis of azacitidine treatment for juvenile myelomonocytic leukemia.
Honda Y; Muramatsu H; Nanjo Y; Hirabayashi S; Meguro T; Yoshida N; Kakuda H; Ozono S; Wakamatsu M; Moritake H; Yasui M; Sano H; Manabe A; Sakashita K
Int J Hematol; 2022 Feb; 115(2):263-268. PubMed ID: 34714526
[TBL] [Abstract][Full Text] [Related]
5. Sustained remission with azacitidine monotherapy and an aberrant precursor B-lymphoblast population in juvenile myelomonocytic leukemia.
Hashmi SK; Punia JN; Marcogliese AN; Gaikwad AS; Fisher KE; Roy A; Rao P; Lopez-Terrada DH; Ringrose J; Loh ML; Niemeyer CM; Rau RE
Pediatr Blood Cancer; 2019 Oct; 66(10):e27905. PubMed ID: 31250550
[TBL] [Abstract][Full Text] [Related]
6. Whole Genome MBD-seq reveals different CpG methylation patterns in Azacytidine-treated Juvenile Myelomonocytic Leukaemia (JMML) patients.
Leoncini PP; Vitullo P; Di Florio F; Tocco V; Cefalo MG; Pitisci A; Girardi K; Niemeyer C; Locatelli F; Bertaina A
Br J Haematol; 2018 Sep; 182(6):909-912. PubMed ID: 28771681
[No Abstract] [Full Text] [Related]
7. Intriguing response to azacitidine in a patient with juvenile myelomonocytic leukemia and monosomy 7.
Furlan I; Batz C; Flotho C; Mohr B; Lübbert M; Suttorp M; Niemeyer CM
Blood; 2009 Mar; 113(12):2867-8. PubMed ID: 19299654
[No Abstract] [Full Text] [Related]
8. Gene mutations do not operate in a vacuum: the increasing importance of epigenetics in juvenile myelomonocytic leukemia.
Flotho C
Epigenetics; 2019 Mar; 14(3):236-244. PubMed ID: 30773984
[TBL] [Abstract][Full Text] [Related]
9. Azacitidine is effective for targeting leukemia-initiating cells in juvenile myelomonocytic leukemia.
Krombholz CF; Gallego-Villar L; Sahoo SS; Panda PK; Wlodarski MW; Aumann K; Hartmann M; Lipka DB; Daskalakis M; Plass C; Niemeyer CM; Erlacher M; Flotho C
Leukemia; 2019 Jul; 33(7):1805-1810. PubMed ID: 30679798
[No Abstract] [Full Text] [Related]
10. Novel approaches to diagnosis and treatment of Juvenile Myelomonocytic Leukemia.
Locatelli F; Algeri M; Merli P; Strocchio L
Expert Rev Hematol; 2018 Feb; 11(2):129-143. PubMed ID: 29279013
[TBL] [Abstract][Full Text] [Related]
11. Response to upfront azacitidine in juvenile myelomonocytic leukemia in the AZA-JMML-001 trial.
Niemeyer CM; Flotho C; Lipka DB; Starý J; Rössig C; Baruchel A; Klingebiel T; Micalizzi C; Michel G; Nysom K; Rives S; Schmugge Liner M; Zecca M; Schönung M; Baumann I; Nöllke P; Benettaib B; Biserna N; Poon J; Simcock M; Patturajan M; Menezes D; Gaudy A; van den Heuvel-Eibrink MM; Locatelli F
Blood Adv; 2021 Jul; 5(14):2901-2908. PubMed ID: 34297046
[TBL] [Abstract][Full Text] [Related]
12. Azacitidine access program for Belgian patients with myelodysplastic syndromes, acute myeloid leukemia or chronic myelomonocytic leukemia.
Meers S; Selleslag D; Potier H; Glasmacher A; Mineur P; Voelter V
Curr Med Res Opin; 2015 Jan; 31(1):35-42. PubMed ID: 25317956
[TBL] [Abstract][Full Text] [Related]
13. [Juvenile myelomonocytic leukemia: A three-case series].
Ghariani I; Jmili-Braham N; Regaieg H; Achour B; Ben Youssef Y; Sendi H; Bakir L; Kortas M
Arch Pediatr; 2016 Dec; 23(12):1264-1269. PubMed ID: 27789175
[TBL] [Abstract][Full Text] [Related]
14. Myeloid leukemoid reaction after initial azacitidine therapy for chronic myelomonocytic leukemia.
Hagino T; Sato T; Saga R; Hidai H; Murai Y; Akiyama H; Motomura S
Int J Hematol; 2022 Dec; 116(6):961-965. PubMed ID: 35852697
[TBL] [Abstract][Full Text] [Related]
15. Juvenile myelomonocytic leukemia with less aggressive clinical course and KRAS mutation.
Imamura M; Imai C; Takachi T; Nemoto T; Tanaka A; Uchiyama M
Pediatr Blood Cancer; 2008 Oct; 51(4):569. PubMed ID: 18561174
[No Abstract] [Full Text] [Related]
16. Myeloid progenitors with PTPN11 and nonRAS pathway gene mutations are refractory to treatment with 6-mercaptopurine in juvenile myelomonocytic leukemia.
Matsuda K; Nakazawa Y; Iwashita C; Kurata T; Hirabayashi K; Saito S; Tanaka M; Yoshikawa K; Yanagisawa R; Sakashita K; Sasaki S; Honda T; Koike K
Leukemia; 2014 Jul; 28(7):1545-8. PubMed ID: 24496301
[No Abstract] [Full Text] [Related]
17. A Case of Uveitis in a Patient With Juvenile Myelomonocytic Leukemia Successfully Treated With Adalimumab.
Cortellazzo Wiel L; Pastore S; Taddio A; Tommasini A
J Pediatr Hematol Oncol; 2020 Jul; 42(5):e373-e376. PubMed ID: 30807392
[TBL] [Abstract][Full Text] [Related]
18. How a rare pediatric neoplasia can give important insights into biological concepts: a perspective on juvenile myelomonocytic leukemia.
Flotho C; Kratz CP; Niemeyer CM
Haematologica; 2007 Nov; 92(11):1441-6. PubMed ID: 18024390
[No Abstract] [Full Text] [Related]
19. Molecular assessment of pretransplant chemotherapy in the treatment of juvenile myelomonocytic leukemia.
Hecht A; Meyer J; Chehab FF; White KL; Magruder K; Dvorak CC; Loh ML; Stieglitz E
Pediatr Blood Cancer; 2019 Nov; 66(11):e27948. PubMed ID: 31347788
[TBL] [Abstract][Full Text] [Related]
20. RAS pathway mutations in juvenile myelomonocytic leukemia.
Emanuel PD
Acta Haematol; 2008; 119(4):207-11. PubMed ID: 18566538
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
